Nurix Therapeutics, Inc. (NRIX) Financial Analysis & Valuation | Quarter Chart
Nurix Therapeutics, Inc. (NRIX)
NRIXPrice: $16.03
Fair Value: 🔒
🔒score
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the tre... more
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and co... more
Description
Shares
| Market Cap | $1.39B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Arthur T. Sands |
| IPO Date | 2020-07-24 | CAGR | 0.12% |
| Employees | 286 | Website | www.nurixtx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.12% | Total Yield | -0.12% |
NRIX chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.76B | P/E Ratio | -5.06 |
| Forward P/E | -5.61 | PEG Ratio | — |
| P/S Ratio | 19.88 | P/B Ratio | 3.77 |
| P/CF Ratio | -6.96 | P/FCF Ratio | -5.25 |
| EPS | $-3.17 | EPS Growth 1Y | 12.86% |
| EPS Growth 3Y | -4.24% | EPS Growth 5Y | 57.21% |
| Revenue Growth 1Y | 27.23% | Gross Margin | -1.39% |
| Operating Margin | -4.39% | Profit Margin | -4.11% |
| ROE | -0.64% | ROA | -0.46% |
| ROCE | -0.58% | Current Ratio | 6.01 |
| Quick Ratio | 6.01 | Cash Ratio | 0.77 |
| Debt/Equity | 0.12 | Interest Coverage | — |
| Altman Z Score | 2.55 | Piotroski Score | 2 |